Perioperative Management of Patients with Prosthetic Heart Valves-A Narrative Review

Abstract

Worldwide, about 13% of the 200,000 annual recipients of prosthetic heart valves (PHV) present for various surgical procedures. Also, more and more females are opting for pregnancies after having PHV. All patients with PHV present unique challenges for the anesthesiologists, surgeons and obstetricians (in case of deliveries). They have to deal with the perioperative management of anticoagulation and a host of other issues involved. We reviewed the English language medical literature relevant to the different aspects of perioperative management of patients with PHV, particularly the guidelines of reputed societies that appeared in the last 20 years. Regression of cardiac pathophysiology following valve replacement is variable both in extent and timeline. The extent to which reverse remodeling occurs depends on the perioperative status of the heart. We discussed the perioperative assessment of patients with PHV, including focused history and relevant investigations with the inferences drawn. We examined the need for prophylaxis against infective endocarditis and management of anticoagulation in such patients in the perioperative period and the guidelines of reputed societies. We also reviewed the conduct of anesthesia, including general and regional anesthesia (neuraxial and peripheral nerve/plexus blocks) in such patients. Finally, we discussed the management of delivery in this group of high-risk patients. From the discussion of different aspects of perioperative management of patients with PHV, we hope to guide in formulating the comprehensive plan of management of safe anesthesia in such patients.

First Observation of Splenic Infarction attributed to Infective Endocarditis in Pregnant Women with a History of MVR: A Case Report

“…(MHV), if labor is premature, CS should be administered when the INR is < 2.0, and patients can transition from oral Valproic Acid (VKA) to LMWH perioperatively. LMWH should be administered twice daily, and oral VKA should be resumed after 24 hours, with LMWH continuing until a therapeutic INR is achieved(17). This is an exceptional case observed in clinical practice.…”